Concentration of furanocoumarin metabolites in urine Not Applicable
Conditions
Interventions
Participants are randomly assigned following simple randomization procedures (computerized random numbers) to one of three treatment groups. The study is a randomized crossover feeding trial. Particip
Sponsors
Centros de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBERobn) (Spain)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Healthy adult males aged 20-35 years
Exclusion criteria
Exclusion criteria: 1. Previous history of cardiovascular disease (ischemic heart disease - angina or recent or old myocardial infarction, cerebral vascular accident, or peripheral vascular disease) 2. Homeostatic disorders 3. Any several chronic diseases 4. Hypertension or dyslipidemia 5. Smoking subjects 6. Alcoholism 7. Other toxic abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Furanocoumarin metabolites will be identified through liquid chromatography coupled to Orbitrap mass spectrometry. Concentrations of furanocoumarins will be determined by liquid chromatography coupled to tandem mass spectrometry (LC?MS/MS). These determinations will be carried out in first morning urine samples collected the day before the first intervention and in the morning following each intervention. | — |
Countries
Spain
Outcome results
None listed